Deep Brain Stimulation for Patients With Advanced Parkinson Disease

Genever, Richard W

doi:10.1001/jama.2009.647

Cited by 1 publication

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…29,31 The incidence of related adverse events, such as infections and device complications, came from previously published studies. 11,32 Data related to treatment costs were based on the clinical diagnosis and treatment of patients with PD in Zhejiang, China. The cost of DBS device was based on data from China Healthcare Security (Supplemental Digital Content, Table S1, http:// links.lww.com/NEU/D522).…”

Section: Datamentioning

confidence: 99%

Deep Brain Stimulation for Advanced Parkinson Disease in Developing Countries: A Cost-Effectiveness Study From China

Guo

Chen

et al. 2022

Neurosurgery

View full text Add to dashboard Cite

BACKGROUND:The cost-effectiveness of deep brain stimulation (DBS) is more favorable than best medical treatment (BMT) for advanced Parkinson disease (PD) in developed countries. However, it remains unclear in developing countries, where the cost of DBS may not be reimbursed by health care system.OBJECTIVE:To model and evaluate the long-term cost-effectiveness of DBS for advanced PD in China from a patient payer perspective.METHODS:We developed a Markov model representing the clinical progress of PD to predict the disease progression and related medical costs in a 15-year time horizon. The incremental cost-effectiveness ratio (ICER) and net benefit were used to evaluate the cost-effectiveness of DBS vs BMT.RESULTS:DBS treatment led to discounted total costs of ¥370 768 ($56 515.20) (95% CI, ¥369 621.53-371 914.88), compared with ¥48 808 ($7439.68) (95% CI, ¥48 502.63-49 114.21) for BMT, with an additional 1.51 quality-adjusted life years gained, resulting in an ICER of ¥213 544 ($32 549.96)/quality-adjusted life years (95% CI, ¥208 177.35-218 910.10). Sensitivity analysis showed that DBS-related cost has the most substantial impact on ICER. Nation-wide net benefit of BMT and DBS were ¥33 819 ($5154.94) (95% CI, ¥30 211.24-37 426) and ¥30 361 ($4627.85) (95% CI, ¥25 587.03-39 433.66), respectively. Patient demographic analysis showed that more favorable DBS cost-effectiveness was associated with younger age and less severe disease stage.CONCLUSION:DBS is cost-effective for patients with advanced PD over a 15-year time horizon in China. However, compared with developed countries, DBS remains a substantial economic burden for patients when no reimbursement is provided. Our findings may help inform cost-effectiveness–based decision making for clinical care of PD in developing countries.

show abstract

Section: Datamentioning

confidence: 99%